TheEdgeResearch
Home / Stocks / BCYC

Bicycle Therapeutics plc (BCYC)

NASDAQ Healthcare Biotechnology
$2.90 ▼ -4.92%
Market Cap
$203.0M
Sector
Healthcare
Industry
Biotechnology
Beta
1.60
52-Wk Range
2.85-7.83
CEO
Kevin Lee
Country
GB
Currency
USD

Bicycle Therapeutics plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, CAM, GB. The stock last traded at $2.90, down 4.92% on the session, giving a market capitalisation of $203.0M. On trailing twelve-month figures it carries a trailing P/E of -1.43, a net margin of -169.8%. Its beta of 1.60 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-1.43
Price / Sales
2.43
Price / Book
0.40
EV / EBITDA
1.88
Gross margin
100.0%
Operating margin
-189.5%
Net margin
-169.8%
Return on equity
—
Debt / equity
0.03
Current ratio
12.09
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
288
IPO date
2019-05-23
Headquarters
Cambridge, CAM, GB
About Bicycle Therapeutics plc

Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.

Comparable companies

Bicycle Therapeutics plc is most often compared with the following Healthcare names:

ADCTCMPXFDMTFULCKALVLXRXNMRAOMERPRTARAPT
More research on BCYC
BCYC technical analysis BCYC TheEdge Score Compare against peers
Open full interactive analysis & DCF →